Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia
Elevated levels of blood lipids are one of the major risk factors for cardiovascular (CV) disease in patients with type 2 diabetes mellitus. Diabetic dyslipidaemia is characterised by the presence of potentially atherogenic lipids, including high levels of plasma triglycerides (TGs), mild-to-moderat...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2020-04-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/10351 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327441652219904 |
|---|---|
| author | Alberto Zambon |
| author_facet | Alberto Zambon |
| author_sort | Alberto Zambon |
| collection | DOAJ |
| description | Elevated levels of blood lipids are one of the major risk factors for cardiovascular (CV) disease in patients with type 2 diabetes mellitus. Diabetic dyslipidaemia is characterised by the presence of potentially atherogenic lipids, including high levels of plasma triglycerides (TGs), mild-to-moderately elevated levels of low-density lipoprotein cholesterol (LDL-C), and low levels of high-density lipoprotein cholesterol (HDL-C). Statin therapy to reduce LDL-C levels is the mainstay of treatment practice to reduce CV risk. However, despite achieving targets for LDL-C, patients with diabetic dyslipidaemia remain at a high risk of residual CV events. Hence there is a need to target other components (i.e. elevated TGs) of the atherogenic dyslipidaemia that are not affected by treatment with statins. This review highlights the clinical benefits of using non-HDL-C, a single marker that includes all atherogenic lipoproteins, as a leading treatment target to reduce the residual CV risk. |
| format | Article |
| id | doaj-art-304a140130e7415caaf4fcf0d307d221 |
| institution | Kabale University |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2020-04-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-304a140130e7415caaf4fcf0d307d2212025-08-20T03:47:53ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782020-04-01231657110.14341/DM1035110594Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemiaAlberto Zambon0University of PadovaElevated levels of blood lipids are one of the major risk factors for cardiovascular (CV) disease in patients with type 2 diabetes mellitus. Diabetic dyslipidaemia is characterised by the presence of potentially atherogenic lipids, including high levels of plasma triglycerides (TGs), mild-to-moderately elevated levels of low-density lipoprotein cholesterol (LDL-C), and low levels of high-density lipoprotein cholesterol (HDL-C). Statin therapy to reduce LDL-C levels is the mainstay of treatment practice to reduce CV risk. However, despite achieving targets for LDL-C, patients with diabetic dyslipidaemia remain at a high risk of residual CV events. Hence there is a need to target other components (i.e. elevated TGs) of the atherogenic dyslipidaemia that are not affected by treatment with statins. This review highlights the clinical benefits of using non-HDL-C, a single marker that includes all atherogenic lipoproteins, as a leading treatment target to reduce the residual CV risk.https://www.dia-endojournals.ru/jour/article/view/10351cardiovascular riskdiabetic dyslipidaemiafenofibratelow-density lipoprotein cholesterolnon-high-density lipoprotein cholesterolstatinstriglyceridesomega-3 fatty acids |
| spellingShingle | Alberto Zambon Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia Сахарный диабет cardiovascular risk diabetic dyslipidaemia fenofibrate low-density lipoprotein cholesterol non-high-density lipoprotein cholesterol statins triglycerides omega-3 fatty acids |
| title | Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia |
| title_full | Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia |
| title_fullStr | Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia |
| title_full_unstemmed | Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia |
| title_short | Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia |
| title_sort | non high density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia |
| topic | cardiovascular risk diabetic dyslipidaemia fenofibrate low-density lipoprotein cholesterol non-high-density lipoprotein cholesterol statins triglycerides omega-3 fatty acids |
| url | https://www.dia-endojournals.ru/jour/article/view/10351 |
| work_keys_str_mv | AT albertozambon nonhighdensitylipoproteincholesterolandcardiovasculardiseaseinpatientswithdiabeticdyslipidaemia |